Though rare, atypical teratoid/rhabdoid tumors (ATRT) remain a clinically challenging pediatric tumor and lack defined treatments. “One-size-fits-all” multimodal regimens have largely been of modest clinical benefits thereby urging the development of precision medicine for ATRT. However, the single- mutation nature of pediatric tumors like ATRT has misrepresented the potential of non-mut…